Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.45 |
| ▸ | QPCT | Q16769 | 1/20 | 0.44 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.42 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4896123 | 0.84 | RAB9A (0.39) | MAPTGABRA1GABRB2 | |
| SCHEMBL5327317 | 0.73 | KDM4E (0.60) | MEN1KMT2AKDM4EMAPTPTGS1 | |
| SCHEMBL28134378 | 0.72 | FFAR1 (0.56) | MEN1KMT2AKDM4EMAPT | |
| SCHEMBL14946884 | 0.72 | MCL1 (0.52) | MEN1KMT2AMCL1GABRA1GABRB2 | |
| SCHEMBL2287125 | 0.70 | RAB9A (0.36) | MEN1KMT2AMAPT | |
| SCHEMBL25080987 | 0.69 | L3MBTL1 (0.46) | MCL1 | |
| SCHEMBL4688360 | 0.69 | MCL1 (0.56) | MEN1KMT2AMCL1GABRA1GABRB2 | |
| SCHEMBL25081015 | 0.68 | FAAH (0.63) | MCL1 | |
| SCHEMBL5353450 | 0.68 | PDE10A (0.44) | MAPT | |
| SCHEMBL12985062 | 0.68 | CYP2E1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080300290-A1 | Novel Beta-Agonists, Process for Their Preparation and Their Use as Medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300290-A1 | Novel Beta-Agonists, Process for Their Preparation and Their Use as Medicaments | ADRB1, ADRB3, ADRB2 | MEN1 3039/4885KMT2A 2675/4885KDM4E 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.